The Rhythm | Issue 10
Issue 10 | Week of 8 June 2026
No major cardiology congress fell this week. The European Renal Association (ERA) Congress in Glasgow, from 3 to 6 June, set the agenda, with the strongest cardiorenal evidence published simultaneously in JAMA and The Lancet.
Cardiology Intelligence Briefing: where evidence stops
Cardiovascular medicine spent this week at the boundary between plausible treatment and proven benefit. In advanced chronic kidney disease, where thrombotic and bleeding risks rise together, adding low-dose anticoagulation to standard care did not reduce cardiovascular events and increased major bleeding.1 In the same cardiorenal territory, pooled finerenone data pointed in the opposite direction: lower kidney disease progression and fewer cardiovascular events, driven by heart failure hospitalisation or cardiovascular death, across diabetic and non-diabetic chronic kidney disease populations.2 The contrast is clinically important. In cardiorenal disease, protection appears to come not from adding more antithrombotic intensity, but from modifying the biology that drives kidney and heart failure risk.
The rest of the week carried the same lesson into more familiar cardiology pathways. After percutaneous coronary intervention, early aspirin withdrawal with continued P2Y12 inhibitor monotherapy preserved major adverse cardiovascular event outcomes and reduced bleeding, but the signal for excess stent thrombosis with very early withdrawal in acute coronary syndrome keeps this from becoming a one-size-fits-all strategy.3 Before cardioversion, smartphone rhythm monitoring reduced avoidable same-day cancellations, a useful service improvement rather than proof of better rhythm outcomes.4 And in a large post-PCI cohort, patients with fewer controlled risk factors before intervention had higher one-year event rates, a reminder that procedural success cannot rescue unfinished secondary prevention.5
This was a quieter week than the recent congress-driven issues, but it had a clear clinical spine. The strongest message was restraint. In advanced kidney disease, after coronary stenting, and before rhythm procedures, the next step is not always to add more treatment. Sometimes the more evidence-based decision is to withhold, simplify, or redirect effort toward the risk factors that should already have been controlled.
